Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Intracerebral Hemorrhage, Stroke, Hypertension
Interventions: Blood pressure management policies; Other
Lead sponsor: The George Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Participants
Interventions: KT-579, Placebo; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Traumatic Brain Injury, Sports Concussion, Sports Injury
Interventions: Banyan Biomarkers; Other
Lead sponsor: Banyan Biomarkers, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
Interventions: Rituximab, Bendamustine, Vincristine sulfate liposome injection; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (BMS-188667), Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 16 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 10
States / cities: Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Adalimumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Rancho Mirage, California • Duncansville, Pennsylvania

Conditions: Prostate Cancer
Interventions: selenomethionine, finasteride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
Interventions: selenomethionine, placebo, cisplatin, radiation therapy, quality-of-life assessment; Dietary Supplement · Other · Drug + 2 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Asthma, Obesity
Interventions: L-ctirulline, Matching Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart, Insulin Lispro; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hyperglucagonemia, Obesity
Interventions: Glucagon, Octreotide, Placebo, Insulin; Drug · Behavioral
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Nivolumab, Cetuximab, Cisplatin, Radiotherapy; Biological · Drug · Radiation
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more

Conditions: Adult Form of Celiac Disease
Interventions: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab, Tiragolumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions: Control: Lacated Ringers, Apocynin, Allopurinol, BH4, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Acetyl-ß-methylcholine chloride; Drug
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions: Cyclosporine, Methylprednisolone and Prednisone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-melanoma Skin Cancer
Interventions: Solaraze and Vaniqa; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: valsartan plus hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Bladder Carcinoma
Interventions: Gabapentin, Placebo, Questionnaire Administration; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pleural Effusion
Interventions: Cathflo Activase, Talc Slurry Pleurodesis; Drug
Lead sponsor: Memorial Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Food Hypersensitivity
Interventions: Extensively hydrolyzed, whey protein infant formula, Extensively hydrolyzed, casein protein infant formula; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 2 Months to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Huntington Beach, California • Roseville, California + 11 more

Conditions: Breast Cancer
Interventions: Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 22
States / cities: Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more

Conditions: Osteoarthritis, Postoperative Pain
Interventions: pregabalin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Northport, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 21 more

Search by objective public record fields.

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

A Evaluation Of Biomarkers Associated With Sports Induced Concussions In College Student Athletes

Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Abatacept With Methotrexate- Phase IIB

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes

Comparison of Insulins Aspart and Lispro in Insulin Pumps

Effects of Glucagon Administration on Energy Expenditure

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

The Effect of Antioxidants on Skin Blood Flow-BH4

Cyclosporine Vs Steroids in DRESS

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

Extensively Hydrolyzed Formula: Hypoallergenicity

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement